89284-11-7

Basic information

• Product Name: 6-Amino-2,3-dibromopyridine
• Synonyms: 6-Amino-2,3-dibromopyridine;5,6-Dibromo-2-pyridinamine;5,6-DibroMo-pyridin-2-ylaMine;2-Pyridinamine, 5,6-dibromo-
• CAS NO: 89284-11-7
• Molecular Formula: C₅H₄Br₂N₂
• Molecular Weight: 251.92
• Mol File: 89284-11-7.mol
• Article Data: 13

Chemical Properties

• Melting Point: 154-155 °C(Solv: benzene (71-43-2))
• Boiling Point: 298.087 °C at 760 mmHg
• Flash Point: 134.078 °C
• Appearance: /
• Density: 2.147 g/cm³
• Vapor Pressure: 0.0013mmHg at 25°C
• Refractive Index: 1.672
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.19±0.10(Predicted)
• CAS DataBase Reference: 6-Amino-2,3-dibromopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Amino-2,3-dibromopyridine(89284-11-7)
• EPA Substance Registry System: 6-Amino-2,3-dibromopyridine(89284-11-7)

Safety Data

• Hazardous Substances Data: 89284-11-7(Hazardous Substances Data)

Usage

General Description

6-Amino-2,3-dibromopyridine is a chemical compound with the molecular formula C5H4Br2N2. It is a heterocyclic aromatic compound that contains a pyridine ring with two bromine atoms and an amino group attached to it. 6-Amino-2,3-dibromopyridine is used as a building block in organic synthesis and can be used in the production of pharmaceuticals and agrochemicals. It is also used as a precursor in research and development for the synthesis of various other chemical compounds. 6-Amino-2,3-dibromopyridine is a white to light brown solid and is moderately soluble in water. It is important to handle this chemical with caution as it may have harmful effects if not used properly.

InChI:InChI=1/C5H4Br2N2/c6-3-1-2-4(8)9-5(3)7/h1-2H,(H2,8,9)

Upstream product

• 2402-92-8 2,3,6-tribromopyridine 
• 19798-81-3 2-Amino-6-bromopyridine 
• 408352-48-7 2-amino-4,6-dibromopyridine 
• 2408-70-0 2,4,6-tribromopyridine 
• 7726-95-6 bromine 
• 64-19-7 acetic acid 

Downstream Products

• 1072-97-5 5-bromo-2-pyridylamine 
• 1211533-83-3 5- bromo-6-methoxypyridin-2-amine 
• 1375707-59-7 N-[6-methoxy-5-(2-methyloxazol-5-yl)-2-pyridyl]-4-methyl-2-(2,2,2-trifluoroethyl)-3,5-dihydro-2H-pyrido[3,2-f][1,4]oxazepin-8-amine 
• 1375707-56-4 N-[6-methoxy-5-(2-methyloxazol-5-yl)-2-pyridyl]-4-methyl-2-(2,2,2-trifluoroethyl)-3,5-dihydro-2H-pyrido[3,2-f][1,4]oxazepin-8-amine 
• 1375712-18-7 (-)-(2S)-2-(5-fluoro-2-pyridyl)-N-[6-methoxy-5-(4-methylimidazol-1-yl)-2-pyridyl]-4,5-dimethyl-3,5-dihydro-2H-pyrido[3,2-f][1,4]oxazepin-8-amine 
• 1375712-15-4 (-)-(2S)-2-(5-fluoro-2-pyridyl)-N-[6-methoxy-5-(4-methylimidazol-1-yl)-2-pyridyl]-4,5-dimethyl-3,5-dihydro-2H-pyrido[3,2-f][1,4]oxazepin-8-amine 
• 1375707-02-0 5-(2-methoxy-6-(4-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-ylamino)pyridin-3-yl)-1-methylpyridin-2(1H)-one 
• 1375706-99-2 5-(2-methoxy-6-(4-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-ylamino)pyridin-3-yl)-1-methylpyridin-2(1H)-one 
• 1375706-81-2 2-(3,3-difluorocyclobutyl)-N-(6-methoxy-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-4-methyl-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine 
• 1375706-84-5 2-(3,3-difluorocyclobutyl)-N-(6-methoxy-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-4-methyl-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine 

Relevant articles and documents

6-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

HPK1 ANTAGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.